A. Nencioni

Type de document

Articles (9)

Co-auteur

Date

Source

Mot-clé

spectacle (6) enzyme (6) Treatment (6) Nicotinamide (6) Human beings (6) ligne (5) cancer (5) Cancer (5) Inhibitors (5) Leukemia (5) Inhibition (5) Cancer cells (5) Cancer (5) Agent (Philosophy) (5) biosynthèse (4) thérapie (4) espèce (4) Therapeutics (4) Species (4) Mice (4) Cell death (4) Biosynthesis (4) Animals (4) Synthesis (4) modèle (3) perte (3) effet (3) survie (3) Development (3) Survival (3)

Documents écrit par A. Nencioni (9) | parle de A. Nencioni (0)

Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
S. Fratta et al. (15 mars 2023)
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
P. Biniecka et al. (16 févr. 2023)
Dendritic cells direct circadian anti-tumour immune responses.
C. Wang et al.
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
M.S. Ghanem et al. (10 juil. 2022)
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
O. ElMokh et al. (8 avr. 2022)
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
A.J. Cloux et al. (19 nov. 2019)
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
A. Cagnetta et al.
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
G. Sociali et al. (19 janv. 2016)
A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
V. Ginet et al. (2014)